Palisade Bio to Participate in Three Major Investor Conferences in September

Denver, CO, Sept. 03, 2026 /CourierPR/ -- Palisade Bio, Inc., a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients with inflammatory and fibrotic diseases, will have key management participate in three major investor conferences in September 2026. The events provide valuable opportunities for the company to engage with investors and further discuss its lead product candidate, PALI-2108.

From September 8 to 10, members of Palisade Bio's management team will attend the Wells Fargo 2026 Healthcare Conference in Boston, Massachusetts. The conference will feature investor meetings, offering a chance for attendees to gain insights into the company's progress and plans.

On September 14 and 15, Palisade Bio's executives will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY. The company will give a presentation on Wednesday, September 16, from 3:00 to 3:30 PM Eastern Time. This event will also include in-person investor meetings, allowing for more in-depth discussions.

The third event, the Morgan Stanley 24th Annual Global Healthcare Conference, will take place in New York, NY, from September 14 to 16. Notable among these is a scheduled in-person fireside chat on Wednesday, September 16, from 10:00 to 10:35 AM Eastern Time. The webcast of this fireside chat will be available on the company’s website for those unable to attend in person.

Palisade Bio is currently advancing its lead clinical product candidate, PALI-2108, into Phase 2 clinical trials for the treatment of inflammatory bowel disease (IBD), specifically including ulcerative colitis (UC) and Crohn’s disease (CD). Despite the availability of multiple biologic and small-molecule therapies, many patients with UC and CD face challenges such as not achieving durable remission, losing response over time, or discontinuing treatment due to safety or tolerability issues. The company believes PALI-2108 could address these limitations through its potential for once-daily oral dosing, targeted lower-intestinal bioactivation, and broad PDE4-mediated anti-inflammatory activity.

Investors interested in meeting with Palisade Bio management during these conferences should contact their respective conference representatives. Live webcasts of the fireside chats will be available on the company’s website, with replays archived for a limited time.